animal-based radiation absorbed dose evaluation of holmium-166 labeled hydroxyapatite particulates in liver malignancies

Objective(s): liver malignancies are among the most prevalent causes of cancer-related deaths worldwide. intra-arterial administration of particulates labeled with beta-emitting radionuclides is one of the non-surgical promising modalities for the treatment of liver cancer.methods: in this work, the radiation absorbed dose of 166ho-hydroxyapatite (166ho-ha) radiopharmaceutical was estimated for adult men based on biodistribution data in normal wistar rats. the mird dose calculation method and the sparks and aydogan methodology were applied.results: the results show that more than 84% of the absorbed dose is localized in liver tissue (7.35 mgy mbq-1). also, radiation absorbed doses of 166ho-ha for red bone marrow, osteogenic cells, and spleen tissues were estimated to be about 0.18, 0.38, and 0.24 mgy mbq-1, respectively. the maximum administrated activity was obtained at 87.5 mbq kg-1 of body weight with an effective dose of 0.39 msv mbq-1. the maximum tolerable dose (mtd) for liver tissue was 6.13 gbq (165.56 mci).conclusion: this study indicated that 166ho-ha can provide an impressive dose for liver cancer malignancies with an insignificant dose to healthy tissues.